Mode of action:
The primary pharmacodynamic effect of Botulinum toxin type A is a chemical denervation of the treated muscle, resulting in a measurable decrease of the compound muscle action potential. This causes a localized reduction of muscle activity. When injected intramuscularly, the toxin induces paralysis of the affected muscle which temporarily reduces muscle activity.
Contraindications:
- Known hypersensitivity to any botulinum toxin products or to any of the excipients.
- Presence of infection at the proposed injection sites.
- Presence of myasthenia gravis, Eaton Lambert Syndrome or amyotrophic lateral sclerosis.
Store in a refrigerator at 2–8°C.
Keep vials in the outer carton in order to protect from light.
Galderma: Relfydess CMI
EMC: https://www.medicines.org.uk/emc/product/100710/smpc
Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.100710.pdf
